Welcome to our dedicated page for Kalaris Therapeutics SEC filings (Ticker: KLRS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Kalaris Therapeutics, Inc. (NASDAQ: KLRS) SEC filings page on Stock Titan brings together the company’s official regulatory disclosures, drawn in real time from the U.S. Securities and Exchange Commission’s EDGAR system. As a Nasdaq-listed clinical-stage biopharmaceutical company, Kalaris files a range of documents that provide insight into its retinal disease programs, corporate structure, and capital markets activity.
Key filings for KLRS include Form 10-K annual reports and Form 10-Q quarterly reports, which describe the company’s business focus on treatments for prevalent retinal diseases, summarize the clinical status of its lead investigational therapy TH103, and present audited and interim financial statements. Form 8-K current reports detail material events such as the completion of the merger that established Kalaris’ current business focus, private placement transactions involving common stock and pre-funded warrants, initial Phase 1a data for TH103 in treatment-naïve neovascular AMD patients, and quarterly financial results.
Investors can also use this page to access proxy materials such as the DEF 14A definitive proxy statement, which explains the company’s governance structure, board composition, equity compensation plans, and the transition from AlloVir, Inc. to Kalaris Therapeutics, Inc. In addition, compensation and appointment details for executives, as well as shareholder meeting information, appear in specific 8-K items and proxy sections.
Stock Titan enhances these filings with AI-powered summaries that highlight the most important points from lengthy documents, helping readers quickly understand clinical development updates, financing terms, and governance changes. Users can review insider and equity-related disclosures, follow the evolution of the TH103 program through successive filings, and track how Kalaris describes its risks and forward-looking statements over time.
Kalaris Therapeutics, Inc. registered up to $100,000,000 of common stock for sale through an at-the-market program with TD Securities (USA) LLC (TD Cowen). The prospectus permits sales from time to time at market prices, including negotiated block trades or sales on The Nasdaq Global Market.
The prospectus states 22,902,418 shares were outstanding as of December 31, 2025 and discloses an illustrative assumed offering price of $5.79 per share used to show dilution. Compensation to TD Cowen is up to 3.0% of gross proceeds and the company may sell shares to TD Cowen as principal. Net proceeds are intended for general corporate purposes including R&D, clinical development, working capital and potential acquisitions.
Kalaris Therapeutics, Inc. is registering for resale up to 5,000,000 shares of its common stock, consisting of 4,200,000 outstanding shares held by selling stockholders and 800,000 shares issuable upon exercise of pre-funded warrants. The company will not receive proceeds from resales, but will receive cash if pre-funded warrants are exercised at an exercise price of $0.0001 per share. The registration implements registration rights granted in connection with a December 17, 2025 private placement in which the company raised aggregate gross proceeds of approximately $50.0 million through the sale of common stock and pre-funded warrants. Resales may occur from time to time in various manners described under the plan of distribution; certain exercise and beneficial ownership limits (a 4.99% default cap, up to 19.99% if elected) apply to the pre-funded warrants.
Kalaris Therapeutics, Inc. announced that Chief Financial Officer Matthew Gall will resign effective April 14, 2026. In connection with his departure, Brett Hagen, the current Chief Accounting Officer and principal accounting officer, will also serve as the company’s principal financial officer from the same date.
The filing outlines Mr. Hagen’s prior senior finance roles at several biopharmaceutical companies and his academic background in accounting and finance. It also notes that he has no family relationships with directors or officers, no related-party transactions requiring disclosure, and that his compensation arrangements remain unchanged.
Kalaris Therapeutics, Inc. is registering up to $350,000,000 of securities on a shelf, including an $100,000,000 program to sell common stock under a sales agreement.
The prospectus covers debt securities, common stock, preferred stock, subscription rights, warrants and units that may be offered "from time to time"; specific terms and distribution methods will be set forth in prospectus supplements. The company has an at-the-market sales agreement with TD Cowen that permits sales of up to $100,000,000 of common stock, with compensation up to 3.0%.
Kalaris Therapeutics, Inc. registers for resale up to 5,000,000 shares of its common stock, consisting of 4,200,000 outstanding shares and 800,000 shares issuable upon exercise of pre-funded warrants. The prospectus covers resales by the selling stockholders; the company will not receive proceeds from resales, although it would receive cash if pre-funded warrants are exercised at an exercise price of $0.0001 per share. The shares were issued in a private placement that generated approximately $50.0 million in gross proceeds at a price of $10.00 per share (and pre-funded warrants at $9.9999), and the registration statement was filed to satisfy registration rights. Shares outstanding were 22,928,303 as of February 28, 2026. The prospectus permits sales on Nasdaq or other methods described under "Plan of Distribution," and notes a Beneficial Ownership Limitation (default 4.99%, adjustable up to 19.99% with notice).
Kalaris Therapeutics Chief Accounting Officer Brett R. Hagen reported an open-market sale of 1,915 shares of common stock at $6.72 per share, leaving no directly held common shares after the transaction. On the prior day, he received a grant of stock options for 60,800 shares of common stock at an exercise price of $6.81 per share, expiring on March 18, 2036. According to the grant terms, 25% of the underlying shares vest on March 19, 2027, with the remainder vesting in equal monthly installments thereafter, subject to continuous service. A footnote clarifies that a previous filing overstated his beneficial ownership by 10 shares, from 1,925 to 1,915, and this has now been corrected.
Morgan Stanley Smith Barney LLC submitted a Form 144 reporting proposed sales tied to multiple parcels of restricted Common stock that vest under a registered plan. The notice lists individual vesting dates and share quantities, including 1,098 shares vesting on 03/18/2025 and smaller tranches across 2024–2025.
The filing enumerates vesting events labeled "Restricted stock vesting under a registered plan" with specific dates and share counts; these entries reflect planned dispositions associated with service‑based vesting rather than an open‑market transaction detail or aggregate registered amount.
Kalaris Therapeutics director and officer Andrew Oxtoby received a stock option grant covering 222,000 shares of Common Stock. The option was granted as a compensation award with an exercise price of $6.8100 per share and expires on March 18, 2036.
The shares underlying the option vest over four years, with 25% vesting on March 19, 2027 and the remaining 75% vesting in equal monthly installments thereafter, subject to continuous service. Following this grant, Oxtoby holds 222,000 derivative securities directly.